DENTSPLY SIRONA (NASDAQ:XRAY) Announces FY 2026 Earnings Guidance

by · The Markets Daily

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.200-1.300 for the period, compared to the consensus earnings per share estimate of 1.470. The company issued revenue guidance of $3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $9.46 on Friday. The stock has a market capitalization of $1.89 billion, a P/E ratio of 6.92, a PEG ratio of 1.27 and a beta of 0.87. The firm’s 50 day moving average is $9.60 and its 200 day moving average is $11.28. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA has a 12 month low of $8.14 and a 12 month high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.02). DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company had revenue of $836.00 million for the quarter, compared to the consensus estimate of $861.68 million. During the same period in the prior year, the firm posted $0.37 EPS. The business’s revenue for the quarter was down 7.5% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. On average, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on XRAY. Mizuho cut their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, October 22nd. Bank of America reaffirmed a “buy” rating on shares of DENTSPLY SIRONA in a research report on Friday. Piper Sandler dropped their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Barclays lifted their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Finally, Leerink Partners decreased their price target on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.64.

Check Out Our Latest Report on DENTSPLY SIRONA

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

About DENTSPLY SIRONA

(Get Free Report)

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

Further Reading